Elite in Japanese Encephalitis

Tomas Jelinek

Berlin, BE, DE 
Elite in Japanese Encephalitis
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Tomas Jelinek practices in Berlin, Germany. Mr. Jelinek is rated as an Elite expert by MediFind in the treatment of Japanese Encephalitis. His top areas of expertise are Japanese Encephalitis, Encephalitis, Togaviridae Disease, and Rabies.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Japanese Encephalitis.

Gender
Male

Locations

Berlin, BE, Germany
Other Locations
Koeln, NW, Germany
Duesseldorf, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) for the Prevention of SARS-CoV-2- Mediated COVID-19 in Participants Aged 12 Years and Older
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

43 Total Publications

Imported Cholera in a German Traveler Returning from Côte d'Ivoire: Rapid Detection of Vibrio Cholerae by syndromic Multiplex PCR Panel.
Imported Cholera in a German Traveler Returning from Côte d'Ivoire: Rapid Detection of Vibrio Cholerae by syndromic Multiplex PCR Panel.
Journal: Journal of travel medicine
Published: September 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jelinek's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile